Ehlers-Danlos Society Pathophysiological and Therapeutic Markers- (RFP) Grant Round 2024 

The Ehlers-Danlos Society aspires to offer grants annually, with calls for clinical research proposals early in the year and for basic science later in the year. They will also offer grants of varying value to reflect the different nature of researcher requirements, including microgrants. The Pathophysiological and Therapeutic Markers RFP Grant Round 2024 aims to advance the understanding of pathophysiology and the utilization of biological markers in hypermobility spectrum disorders (HSD) and the Ehlers-Danlos syndromes (EDS). This initiative seeks to address critical issues by encouraging multidisciplinary teams to investigate specific patient populations and underlying biological mechanisms, fostering collaboration for the benefit of affected communities. Clear criteria and study designs are vital for this research round. 

The Ehlers-Danlos Society invites research proposals to advance the understanding of pathophysiology and the utilization of biological markers in HSD and EDS. Recognizing the novelty of areas such as epigenomics, transcriptomics, proteomics, metabolomics, and tissue histology in HSD and EDS research, the commitment is to provide sustained annual support across the translational pathway, fostering bidirectional collaboration between basic and clinical research.  

In line with research priorities, the key areas of interest and criteria for applications include: 

• The identification of diagnostic or susceptibility biomarkers to detect or confirm the presence of HSD or hypermobile EDS (hEDS) or indicate the potential for developing either of these or any of their comorbidities. 
• The identification of pathophysiological markers that demonstrate potential pathways for therapeutic interventions in any type of EDS or HSD. 
• The exploration of existing markers in any type of EDS or HSD for their potential in monitoring therapeutic interventions, including predictive, responsive, and safety/monitoring markers, to identify individuals more likely than similar individuals without the biomarker to experience a favorable or unfavorable effect from exposure to a medical product or an environmental agent. 
• Prognostic biomarkers that identify the likelihood of a clinical event or disease progression in HSD or EDS. 

Funding 

• They have allocated a total of $900,000 with the goal of funding 3-4 studies. Each grant is intended to cover expenses up to $300,000. The Indirect Cost percentage allowed for this study is 5%.

Check : Internet Society Foundation’s Resiliency Program 2024

Eligibility of Pathophysiological and Therapeutic Markers

• Research proposals should demonstrate meeting one or more of the above criteria.
• Studies involving biomarkers such as imaging characteristics and not primarily addressing the field of epigenetics, transcriptomics, proteomics, metabolomics or histology will not be considered in this RFP.

Also Check : Global Education Challenge 2024

Join us on Telegram for more opportunities!